抗IgE单克隆抗体联合变应原特异性免疫治疗的应用进展
收稿日期: 2022-08-08
网络出版日期: 2024-03-06
基金资助
国家自然科学基金面上项目(81870023);浙江省自然科学基金(LQ20H190006);浙江省重点研发计划项目(2020C03062)
Advances in the application of anti-IgE monoclonal antibodies combined with allergen immunotherapy
Received date: 2022-08-08
Online published: 2024-03-06
抗IgE单克隆抗体目前已被批准用于治疗哮喘和慢性荨麻疹，同时抗IgE单克隆抗体联合变应原特异性免疫治疗（AIT）作为过敏性疾病的辅助治疗已引起普遍关注。研究表明，在AIT治疗中或治疗前添加抗IgE单克隆抗体可显著减少AIT不良反应的发生频率和严重程度，明显改善症状评分，缩短达到维持剂量所需的时间。目前仍需要更大规模的高质量对照试验更好地识别抗IgE单克隆抗体联合AIT的获益人群，以及治疗最佳剂量和持续时间，并评估长期效益、进行成本-效益分析。本文就抗IgE单克隆抗体在AIT中作为辅助治疗的应用进展进行综述。
关键词： 抗IgE单克隆抗体; 变应原特异性免疫治疗; 辅助治疗
李淑娴 , 刘金玲 , 何静 综述 , 陈志敏 审校 . 抗IgE单克隆抗体联合变应原特异性免疫治疗的应用进展[J]. 临床儿科杂志, 2024 , 42(3) : 264 -269 . DOI: 10.12372/jcp.2024.22e1077
Anti-IgE monoclonal antibodies have been approved for the treatment of asthma and chronic urticaria, and anti-IgE monoclonal antibodies combined with allergen immunotherapy (AIT) have attracted widespread attention as an adjunctive therapy for allergic diseases. Studies have shown that the addition of anti-IgE monoclonal antibodies during or before AIT treatment significantly reduces the frequency and severity of AIT adverse reactions, significantly improves the symptom scores, and shortens the time required to achieve maintenance doses. Larger, high-quality, placebo-controlled trials are still needed to better identify the beneficiaries of anti-IgE monoclonal antibodies in conjunction with AIT, as well as the optimal dose and duration of treatment, and to assess long-term benefits and conduct cost-benefit analysis. This article reviews the application of anti-IgE monoclonal antibodies as adjunctive therapy in AIT.
| [1] | Jones CJ, Paudyal P, West RM, et al. Burden of allergic disease among ethnic minority groups in high-income countries[J]. Clin Exp Allergy, 2022, 52(5): 604-615. |
| [2] | Bousquet J, Pfaar O, Agache I, et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy[J]. Clin Transl Allergy, 2021, 11(4): e12014. |
| [3] | Shamji MH, Sharif H, Layhadi JA, et al. Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma[J]. J Allergy Clin Immunol, 2022, 149(3): 791-801. |
| [4] | Golden DBK. Venom Immunotherapy: Questions and Controversies[J]. Immunol Allergy Clin North Am, 2020, 40(1): 59-68. |
| [5] | Dantzer JA, Wood RA. Omalizumab as an adjuvant in food allergen immunotherapy[J]. Curr Opin Allergy Clin Immunol, 2021, 21(3): 278-285. |
| [6] | Aue A, Ho J, Zhu R, et al. Systemic reactions to subcutaneous allergen immunotherapy: real-world cause and effect modelling[J]. Allergy Asthma Clin Immunol, 2021, 17(1): 65. |
| [7] | 国家呼吸系统疾病临床医学研究中心, 中华医学会儿科学分会呼吸学组哮喘协作组, 中国医药教育协会儿科专业委员会, 等. 奥马珠单抗在儿童过敏性哮喘临床应用专家共识[J]. 中华实用儿科临床杂志, 2021, 36(12): 881-890. |
| [8] | 中华医学会皮肤性病学分会荨麻疹研究中心. 抗IgE疗法——奥马珠单抗治疗慢性荨麻疹专家共识[J]. 中华皮肤科杂志, 2021, 54(12): 1057-1062. |
| [9] | Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 2002, 109(2): 274-280. |
| [10] | Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously[J]. Pediatr Allergy Immunol, 2010, 21(1 Pt 2):e160-e165. |
| [11] | Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma[J]. Clin Exp Allergy, 2009, 39(2): 271-279. |
| [12] | Kopp MV, Hamelmann E, Bendiks M, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy[J]. Pediatr Allergy Immunol, 2013, 24(5): 427-433. |
| [13] | Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis[J]. J Allergy Clin Immunol, 2006, 117(1): 1134-140. |
| [14] | Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma[J]. J Allergy Clin Immunol, 2010, 125(2): 383-389. |
| [15] | Valdesoiro-Navarrete L, Leon ME, Rodriguez M, et al. Combination therapy of specific aeroallergens immunotherapy and omalizumab, in children with severe asthma[J]. Allergol Immunopathol (Madr), 2022, 50(2): 1-6. |
| [16] | 王雪艳, 刘长山, 王肖玲, 等. 抗IgE治疗与皮下免疫治疗在儿童过敏性哮喘中的联合应用[J]. 中华实用儿科临床杂志, 2021, 36(12): 941-945. |
| [17] | Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding[J]. J Allergy Clin Immunol, 2007, 120(3): 688-695. |
| [18] | Har D, Lee MJ. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma[J]. Allergy Asthma Proc, 2019, 40(1): 35-40. |
| [19] | Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy[J]. N Engl J Med, 2003, 348(11): 986-993. |
| [20] | Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy[J]. J Allergy Clin Immunol, 2011, 127(6): 1622-1624. |
| [21] | Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy[J]. J Allergy Clin Immunol, 2016, 137(4): 1103-1010. |
| [22] | Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial[J]. Sci Rep, 2017, 7(1): 17453. |
| [23] | Martorell-Calatayud C, Michavila-Gomez A, Martorell-Aragones A, et al. Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy[J]. Pediatr Allergy Immunol, 2016, 27(5): 544-546. |
| [24] | Schneider LC, Rachid R, LeBovidge J, et al. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients[J]. J Allergy Clin Immunol, 2013, 132(6): 1368-1374. |
| [25] | Yee CSK, Albuhairi S, Noh E, et al. Long-term outcome of peanut oral immunotherapy facilitated initially by omalizumab[J]. J Allergy Clin Immunol Pract, 2019, 7(2): 451-461. |
| [26] | Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents[J]. Clin Exp Allergy, 2019, 49(10): 1328-1341. |
| [27] | MacGinnitie AJ, Rachid R, Gragg H, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy[J]. J Allergy Clin Immunol, 2017, 139(3): 873-881. |
| [28] | Begin P, Dominguez T, Wilson SP, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using omalizumab[J]. Allergy Asthma Clin Immunol, 2014, 10(1): 7. |
| [29] | Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 85-94. |
| [30] | Andorf S, Purington N, Kumar D, et al. A phase 2 randomized controlled multisite study using omalizumab-facilitated rapid desensitization to test continued vs discontinued dosing in multifood allergic individuals[J]. EClinicalMedicine, 2019, 7: 27-38. |
| [31] | Azzano P, Paquin M, Langlois A, et al. Determinants of omalizumab dose-related efficacy in oral immunotherapy: evidence from a cohort of 181 patients[J]. J Allergy Clin Immunol, 2021, 147(1): 233-243. |
| [32] | Golden DB, Demain J, Freeman T, et al. Stinging insect hypersensitivity: a practice parameter update 2016[J]. Ann Allergy Asthma Immunol, 2017, 118(1): 28-54. |
| [33] | Sahiner UM, Durham SR. Hymenoptera venom allergy: how does venom immunotherapy prevent anaphylaxis from bee and wasp stings?[J]. Front Immunol, 2019, 10: 1959. |
| [34] | Droitcourt C, Ponvert C, Dupuy A, et al. Efficacy of a short pretreatment with omalizumab in children with anaphylaxis to hymenoptera venom immunotherapy: A report of three cases[J]. Allergol Int, 2019, 68(2): 268-269. |
| [35] | Gulsen A, Rueff F, Jappe U. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis[J]. Allergol Select, 2021, 5: 128-132. |
| [36] | Yilmaz I, Bahcecioglu SN, Turk M. Combination of omalizumab and bee venom immunotherapy: does it work?[J]. Asia Pac Allergy, 2018, 8(1): e2. |
| [37] | Stretz E, Oppel EM, Rawer HC, et al. Overcoming severe adverse reactions to venom immunotherapy using anti-IgE antibodies in combination with a high maintenance dose[J]. Clin Exp Allergy, 2017, 47(12): 1631-1639. |
| [38] | 中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354. |
| [39] | Ledford DK. Omalizumab: overview of pharmacology and efficacy in asthma[J]. Expert Opin Biol Ther, 2009, 9(7): 933-943. |
| [40] | Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper[J]. Allergy, 2017, 72(8): 1156-1173. |
| [41] | Manohar M, Dunham D, Gupta S, et al. Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab[J]. Allergy, 2021, 76(9): 2809-2826. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
